thesis-toulmin
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7C
Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7C
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms
P2860
Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e3f81e4129efdf32bc4cb6a611623c10cb8fe61c
P2860
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.